Search Results
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
The QUAZAR AML-001 Maintenance Trial (Oral Formulation of Azacitidine in AML First Remission
Long-term OS with oral azacitidine in patients with acute myeloid leukaemia in first remission a...
Phase I trial results for oral azacitidine and venetoclax in R/R AML
Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML
Maintenance therapy in AML: agents under investigation and future outlooks
OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML
New developments in AML treatment
Why maintenance therapy in AML is unnecessary
How does maintenance therapy benefit patients with AML? #AML
Azacitidine and venetoclax maintenance post alloSCT in high-risk T-ALL
